Biogen Idec, Samsung Bioepis Target Anti-TNF Biosimilars in Europe - - BioPharm International

ADVERTISEMENT

Biogen Idec, Samsung Bioepis Target Anti-TNF Biosimilars in Europe



Biogen Idec and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis and Crohn’s disease. Under the agreement, Biogen Idec will be responsible for commercialization of these product candidates across Europe, where there already exists a strong market for biosimilars and a defined regulatory pathway. The agreement with Samsung Bioepis aligns with Biogen Idec’s broader corporate objectives of remaining focused on its core business while applying expertise in manufacturing and specialty markets to meet the need for biosimilar therapies.

In February 2013, Samsung Bioepis and Merck & Co (known as MDS outside the United States) formed an agreement to develop and commercialize multiple prespecified and undisclosed biosimilar candidates. Under that agreement, Samsung Bioepis is responsible for preclinical and clinical development, process development and manufacturing, clinical trials and registration. Merck will be responsible for commercialization. Samsung Bioepis will receive an upfront payment from Merck, product supply income, and will be eligible for additional payments associated with prespecified clinical and regulatory milestones. Further financial terms were not disclosed. 

Source: Biogen Idec

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines

Click here